Posts Tagged ‘Wegovy’

The Dark Art of Pharmacy Benefit Managers

May 24, 2022 — Drug pricing has been getting a lot of attention for some time now, so it’s no surprise that the prices of obesity medicines would get attention, too. New medicines are coming, competition will be increasing, and one factor in that competition will be prices. The only way to get good value is to consider both […]

Tirzepatide Pricing Comes in Similar to Semaglutide

May 21, 2022 — Competition can be a great thing. In the past few weeks we’ve been hearing a lot about tirzepatide. The FDA just approved it for treating type 2 diabetes, hailing it as an important advance. Tirzepatide for obesity is a couple of years away, but the initial results of pivotal studies have been extremely impressive. So […]

Why Is Semaglutide More Expensive for Obesity?

May 12, 2022 — Somehow this doesn’t seem right. The list price for for a month’s supply of semaglutide when it’s for diabetes is $892. No matter whether you need a dose of 1 mg, or the new high dose of 2 mg, the price is the same. It goes under the brand name of Ozempic and comes from […]

New Semaglutide Dose in Diabetes: Value for Obesity?

March 31, 2022 — This is the kind of change that flies under the radar and makes a big difference. This week, Novo Nordisk received FDA approval of a 2 mg dose of semaglutide (Ozempic®) for better control of type 2 diabetes. This higher dose option provides a means for maintaining better glycemic control in patients as their disease […]

Racing Toward Better Anti-Obesity Medicines

February 9, 2022 — There’s a race heating up. It is a race to open the way for better obesity care and deliver better options. In this race, semaglutide (Wegovy™) has a head start. But a pack of other options are on the way. Yesterday in JAMA, results in a study of tirzepatide for treating type 2 diabetes tell […]

The Ten Most Read Stories of 2021 on ConscienHealth

December 27, 2021 — Our readers amaze us. First of all, it is amazing that more than 100,000 of you come to ConscienHealth in the span of a year. But more important, you teach us by what you read and share from our site and what you pass up. So here are the top ten stories you read most […]

Wegovy: Disrupting Obesity Care and Supply Chains

December 18, 2021 — Novo Nordisk has a problem. Yesterday its stock lost 16 billion dollars from its value. This is because the company is hitting some bumps in its journey through the uncharted territory of obesity care. For more than a decade now, Novo has been investing in a genuine effort to meet a need for better obesity […]

Tirzepatide Shows Good Weight Outcomes in Diabetes

October 20, 2021 — Day by day, the prospects for treating obesity are getting better. Late on Monday, detailed results from the longest study yet of tirzepatide came out in Lancet. This was a study using this new drug in people with type 2 diabetes, but the average BMI of these patients was 33. None of them had a […]

Innovation and Competition in Obesity Gains Momentum

August 9, 2021 — Could it be that innovation and competition for better obesity care will overtake the health problem of obesity? We see several signs pointing to this. A decade ago, it was tough to get FDA to take obesity innovation seriously. So big pharma research was running from the challenge. Sanofi had invested heavily in developing rimonabant […]

If Wegovy Is a “Game Changer,” What Comes Next?

June 8, 2021 — The mantra for the Wegovy brand of semaglutide just approved by FDA for obesity is clear enough – game changer. Great. Obesity is not a game, but health plans treat it like a 19th century game of hot potato: “Jack’s alive, and likely to live If he dies in your hand, you’ve a forfeit to […]